JAK2 and acute lymphoblastic leukemia: In this article we functionally validated JAK2 Y1007-1008 as a new therapeutic target to reverse therapy resistance by in vitro treatment with ruxolitinib, an already FDA approved JAK1/2 inhibitor [15,16] that is currently also being evaluated for the treatment of B-ALL (NCT02723994) [17], alone or in combination with dexamethasone, in cell lines and in one T-LBL pediatric primary sample.